These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6745084)

  • 21. Anisodamine at higher concentrations in inhibiting alpha-adrenergic responses in isolated canine blood vessels.
    Guo HY; Lorenz RR; Vanhoutte PM
    Chin Med J (Engl); 1993 Jun; 106(6):452-7. PubMed ID: 7900973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of cooperativity on the determination of dissociation constants: examination of the Cheng-Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations.
    Cheng HC
    Pharmacol Res; 2004 Jul; 50(1):21-40. PubMed ID: 15082026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
    Barrondo S; Sallés J
    Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium.
    Bockman CS; Jeffries WB; Abel PW
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1126-33. PubMed ID: 7903385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of antagonist dose-response curves for estimation of pA2-values by Schild-plot analysis and detection of allosteric interactions.
    Pöch G; Brunner F; Kühberger E
    Br J Pharmacol; 1992 Jul; 106(3):710-6. PubMed ID: 1504755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations.
    Cheng HC
    J Pharmacol Toxicol Methods; 2001; 46(2):61-71. PubMed ID: 12481843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between drugs and occupied receptors.
    Tallarida RJ
    Pharmacol Ther; 2007 Jan; 113(1):197-209. PubMed ID: 17079019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computerized graphic methods for determining dissociation constants of agonists, partial agonists, and competitive antagonists in isolated smooth muscle preparations.
    Zaborowsky BR; McMahan WC; Griffin WA; Norris FH; Ruffolo RR
    J Pharmacol Methods; 1980 Sep; 4(2):165-78. PubMed ID: 7453193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic methods for identification of receptors.
    Tallarida RJ
    Life Sci; 1988; 43(26):2169-76. PubMed ID: 2850427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simple pA2 estimation of partial agonists: comparison with the Kaumann-Blinks method.
    Pöch G; Zimmermann I
    J Pharmacol Methods; 1988 Mar; 19(1):47-56. PubMed ID: 3367648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 'rogue' points on non-linear fitting.
    Barlow RB
    Trends Pharmacol Sci; 1993 Nov; 14(11):399-403. PubMed ID: 8296398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor regulation, competitive antagonism and pA2.
    Tallarida RJ; Raffa RB
    Life Sci; 1992; 51(7):PL61-5. PubMed ID: 1640794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How we describe competitive antagonists: three questions of usage.
    Jenkinson DH
    Trends Pharmacol Sci; 1991 Feb; 12(2):53-4. PubMed ID: 2024288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control and stability of ligand receptor interaction in the presence of a competitive compound.
    Tallarida RJ; Freeman KA
    Life Sci; 1991; 48(6):PL19-24. PubMed ID: 1846933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of competitive agonist-antagonist interactions by nonlinear regression.
    Lew MJ; Angus JA
    Trends Pharmacol Sci; 1995 Oct; 16(10):328-37. PubMed ID: 7491710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can equal pA2 values be compatible with receptor differences?
    Raffa RB; Vaught JL; Porreca F
    Trends Pharmacol Sci; 1989 May; 10(5):183-5. PubMed ID: 2667226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The quantification of relative efficacy of agonists.
    Kenakin TP
    J Pharmacol Methods; 1985 Jul; 13(4):281-308. PubMed ID: 2991665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An alternative method to evaluate the nature of an antagonist and its potency: a theoretical approach.
    Calderone V
    J Pharmacol Toxicol Methods; 1998 Apr; 39(3):129-35. PubMed ID: 9741386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs and receptors. An overview of the current state of knowledge.
    Kenakin T
    Drugs; 1990 Nov; 40(5):666-87. PubMed ID: 2292230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications.
    Hoffman A; Goldberg A
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):449-68. PubMed ID: 7473076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.